Drug Trial Radar · NCT04919135
Mesenchymal Stem/Stromal Cell Therapy in the Treatment of Frailty
Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
158
Actual
Start
Oct 19, 2021
Primary completion
Apr 20, 2023
Study completion Dec 30, 2024
Sponsor
- Lead sponsor
- Vinmec Research Institute of Stem Cell and Gene TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is to investigate the safety and potential therapeutic efficacy of allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) in combination with standard frailty treatment in Vietnam
Conditions
- Frailty
Interventions
Umbilical Cord Mesenchymal Stem Cells transplantationBiological
Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the IV route with a 3-month intervening interval
standard frailty treatment and supplementary medicationDrug
Hightamine (Hankook Korus Pharm, Korea), Total calcium (Nugale Pharmaceutical, Canada), Bioflex (Ausbiomed, Australia)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events and serious adverse eventsTime frame: up to the 9-month period following treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vinmec Research Institute of Stem Cell and Gene Technology
Hanoi, Hanoi, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.